Description
A combination of growth hormone (GH) releasing peptides can lead to tremendous increases in GH levels, but such a process generally only requires a growth hormone releasing hormone (GHRH) analogue like sermorelin and a growth hormone secretagogue/ghrelin analogue like GHRP-2 or GHRP-6. Combining all three isn’t likely to cause a proportionally greater increase in GH hormone levels, but are other reasons to utilize such a combination.
Sermorelin is an excellent GHRH analogue with strong GH releasing action and very few off-target effects. In addition., the peptide has been found in animal studies to improve heart health, increase bone density, improve renal function, and possibly even fight off the effects of dementia. GHRP-2 not only helps to build muscle, but has been shown to enhance muscle structure as well. It is also a strong appetite stimulant, improves heart function, boosts immune function, reduces pain perception, and benefits sleep quality. GHRP-6 has been shown to protect brain tissue, enhance memory, boost wound repair, and modulate reward-seeking behavior.
The above list of effects demonstrates both common overlap as well as complimentary features for the peptides above. By combining a GHRH analogue and a ghrelin analogue, maximal growth hormone release is achieved. By combining all three peptides in the correct way (e.g. alternating GHRP-6 with GHRP-2 dosing), it is possible to also amplify the peptides’ secondary effects and achieve additional benefits such as enhanced bone deposition, improved brain protection, and more.
What Is GHRP-6?
GHRP-6 is an effective stimulator of natural Growth Hormone Release from the anterior pituitary. GHRP-6 is also a ghrelin/growth hormone receptor agonist and one of a handful of ghrelin analogues developed in the last several decades. It has been found to have positive effects on heart muscle cells, memory formation, scar formation, sex motivation, and the neurons involved in Parkinson’s disease. GHRP-6 is orally and sublingually active and moderately to highly selective.
GHRP-6 Structure
Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys
Molecular Formula: C46H56N12O6
Molecular Weight: 873.032 g/mol
PubChem CID: 9919153
CAS Number: 87616-84-0
What is GHRP-2?
GHRP-2 (a.k.a. pralmorelin) is a synthetic growth hormone secretagogue known to bind to the ghrelin/growth hormone secretagogue receptor. It was the first of the growth hormone secretagogues to be introduced and is currently marketed as a test peptide for the assessment of growth hormone deficiency and secondary adrenal failure. GHRP-2 has been investigated in stage II clinical trials for the assessment of short stature and is under active research for its effects on appetite, muscle growth, the immune system, and sleep cycles. GHRP-2 is orally and sublingually active, so it does not have to be injected to have its effects.
GHRP-2 Structure
Sequence: D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys
Molecular Formula: C45H55N9O6
Molecular Weight: 817.9749 g/mol
PubChem CID: 6918245
CAS Number: 158861-67-7
Code Names: KP-102, GPA-748, WAY-GPA-748
What Is Sermorelin?
Sermorelin is one of a handful of growth hormone releasing hormone (GHRH) analogues that have been developed in recent years in an effort to preserve some of the positive effects of natural GHRH while avoiding undesirable effects. Sermorelin (Geref) is currently used clinically to assess growth hormone secretion, but the peptide is of additional interest for its abilities to:
- reduce scarring following heart attack,
- increase bone density,
- improve nutrition in chronic illness,
- improve renal function,
- fight the effects of dementia, and
- reduce seizure activity.
Sermorelin Peptide Structure
Sequence: Tyr-Ala-Asp-Ala-lle-Phe-DL-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Molecular Formula: C149H246N44O42S
Molecular Weight: 3357.933 g/mol
PubChem CID: 16129620
CJC-1295 Overview
Growth hormone releasing hormone (GHRH) has been modified a number of times to produce analogues that preserve some of the hormone’s effects while eliminating others. One of those modifications, CJC-1295, consists of just the first 29 amino acids of GHRH. This analogue of GHRH, which is technically a maleimido derivative of hGRF(1-29), was created in an effort to produce a more soluble GH secretagogue that is easier to produce in large quantities but still preserves the physiologic actions of GHRH.
CJC-1295-DAC Structure
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol
PubChem CID: 91976842
